314 related articles for article (PubMed ID: 22967815)
1. NMR-based metabolomics study of canine bladder cancer.
Zhang J; Wei S; Liu L; Nagana Gowda GA; Bonney P; Stewart J; Knapp DW; Raftery D
Biochim Biophys Acta; 2012 Nov; 1822(11):1807-14. PubMed ID: 22967815
[TBL] [Abstract][Full Text] [Related]
2. Re: NMR-based metabolomics study of canine bladder cancer.
Atala A
J Urol; 2013 Aug; 190(2):808. PubMed ID: 23845377
[No Abstract] [Full Text] [Related]
3. MicroRNA profiling of dogs with transitional cell carcinoma of the bladder using blood and urine samples.
Kent MS; Zwingenberger A; Westropp JL; Barrett LE; Durbin-Johnson BP; Ghosh P; Vinall RL
BMC Vet Res; 2017 Nov; 13(1):339. PubMed ID: 29141625
[TBL] [Abstract][Full Text] [Related]
4. Urinary bladder cancer in dogs, a naturally occurring model for cancer biology and drug development.
Knapp DW; Ramos-Vara JA; Moore GE; Dhawan D; Bonney PL; Young KE
ILAR J; 2014; 55(1):100-18. PubMed ID: 24936033
[TBL] [Abstract][Full Text] [Related]
5. High urine concentrations of basic fibroblast growth factor in dogs with bladder cancer.
Allen DK; Waters DJ; Knapp DW; Kuczek T
J Vet Intern Med; 1996; 10(4):231-4. PubMed ID: 8819047
[TBL] [Abstract][Full Text] [Related]
6. Current Status of Urinary Biomarkers for Detection and Surveillance of Bladder Cancer.
Mbeutcha A; Lucca I; Mathieu R; Lotan Y; Shariat SF
Urol Clin North Am; 2016 Feb; 43(1):47-62. PubMed ID: 26614028
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of microsatellite instability in urine for the diagnosis of transitional cell carcinoma of the lower urinary tract in dogs.
Sotirakopoulos AJ; Armstrong PJ; Heath L; Madrill NJ; McNiel EA
J Vet Intern Med; 2010; 24(6):1445-51. PubMed ID: 21039871
[TBL] [Abstract][Full Text] [Related]
8. Expression of cell cycle regulators, 14-3-3σ and p53 proteins, and vimentin in canine transitional cell carcinoma of the urinary bladder.
Suárez-Bonnet A; Herráez P; Aguirre M; Suárez-Bonnet E; Andrada M; Rodríguez F; Espinosa de Los Monteros A
Urol Oncol; 2015 Jul; 33(7):332.e1-7. PubMed ID: 25979650
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the NMP22 test and comparison with voided urine cytology in the detection of bladder cancer.
Lee KH
Yonsei Med J; 2001 Feb; 42(1):14-8. PubMed ID: 11293494
[TBL] [Abstract][Full Text] [Related]
10. Highly sensitive and specific novel biomarkers for the diagnosis of transitional bladder carcinoma.
Kumar P; Nandi S; Tan TZ; Ler SG; Chia KS; Lim WY; Bütow Z; Vordos D; De la Taille A; Al-Haddawi M; Raida M; Beyer B; Ricci E; Colombel M; Chong TW; Chiong E; Soo R; Park MK; Ha HK; Gunaratne J; Thiery JP
Oncotarget; 2015 May; 6(15):13539-49. PubMed ID: 25915536
[TBL] [Abstract][Full Text] [Related]
11. Ultrasonographic findings related to prognosis in canine transitional cell carcinoma.
Hanazono K; Fukumoto S; Endo Y; Ueno H; Kadosawa T; Uchide T
Vet Radiol Ultrasound; 2014; 55(1):79-84. PubMed ID: 23890180
[TBL] [Abstract][Full Text] [Related]
12. Screening for canine transitional cell carcinoma (TCC) by SERS-based quantitative urine cytology.
Pallaoro A; Mirsafavi RY; Culp WTN; Braun GB; Meinhart CD; Moskovits M
Nanomedicine; 2018 Jun; 14(4):1279-1287. PubMed ID: 29597048
[TBL] [Abstract][Full Text] [Related]
13. Discovery and validation of potential urinary biomarkers for bladder cancer diagnosis using a pseudotargeted GC-MS metabolomics method.
Zhou Y; Song R; Ma C; Zhou L; Liu X; Yin P; Zhang Z; Sun Y; Xu C; Lu X; Xu G
Oncotarget; 2017 Mar; 8(13):20719-20728. PubMed ID: 28157703
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of a bladder tumor antigen test as a screening test for transitional cell carcinoma of the lower urinary tract in dogs.
Henry CJ; Tyler JW; McEntee MC; Stokol T; Rogers KS; Chun R; Garrett LD; McCaw DL; Higginbotham ML; Flessland KA; Stokes PK
Am J Vet Res; 2003 Aug; 64(8):1017-20. PubMed ID: 12926595
[TBL] [Abstract][Full Text] [Related]
15. Quantitation of Aurora kinase A gene copy number in urine sediments and bladder cancer detection.
Park HS; Park WS; Bondaruk J; Tanaka N; Katayama H; Lee S; Spiess PE; Steinberg JR; Wang Z; Katz RL; Dinney C; Elias KJ; Lotan Y; Naeem RC; Baggerly K; Sen S; Grossman HB; Czerniak B
J Natl Cancer Inst; 2008 Oct; 100(19):1401-11. PubMed ID: 18812553
[TBL] [Abstract][Full Text] [Related]
16. Management of transitional cell carcinoma of the urinary bladder in dogs: a review.
Fulkerson CM; Knapp DW
Vet J; 2015 Aug; 205(2):217-25. PubMed ID: 25747698
[TBL] [Abstract][Full Text] [Related]
17. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice.
May M; Hakenberg OW; Gunia S; Pohling P; Helke C; Lübbe L; Nowack R; Siegsmund M; Hoschke B
Urology; 2007 Sep; 70(3):449-53. PubMed ID: 17688921
[TBL] [Abstract][Full Text] [Related]
18. Canine invasive transitional cell carcinoma cell lines: in vitro tools to complement a relevant animal model of invasive urinary bladder cancer.
Dhawan D; Ramos-Vara JA; Stewart JC; Zheng R; Knapp DW
Urol Oncol; 2009; 27(3):284-92. PubMed ID: 18562222
[TBL] [Abstract][Full Text] [Related]
19. Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer.
Svatek RS; Herman MP; Lotan Y; Casella R; Hsieh JT; Sagalowsky AI; Shariat SF
Cancer; 2006 Apr; 106(8):1701-7. PubMed ID: 16541433
[TBL] [Abstract][Full Text] [Related]
20. Investigation of the urinary metabolic variations and the application in bladder cancer biomarker discovery.
Liu X; Cheng X; Liu X; He L; Zhang W; Wang Y; Sun W; Ji Z
Int J Cancer; 2018 Jul; 143(2):408-418. PubMed ID: 29451296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
